What's Happening?
The Department of Health and Social Care (DHSC) has announced the procurement of additional volumes of pancreatic enzyme replacement therapy (PERT) to mitigate ongoing supply issues. PERT is essential for individuals with pancreatic insufficiencies, such
as those suffering from pancreatitis, pancreatic cancer, and cystic fibrosis. The DHSC is actively collaborating with suppliers to ensure the availability of PERT through 2025, with plans to address supply needs for 2026. This follows a national patient safety alert in May 2024, which highlighted disruptions in PERT supply expected to last until 2026. The DHSC has also engaged specialist importers to source unlicensed stock to fill market gaps and has provided guidance to healthcare professionals on managing patient care during these disruptions.
Why It's Important?
The availability of PERT is crucial for patients with pancreatic insufficiencies, as it aids digestion and nutrient absorption. The shortage has posed significant health risks, including stress and anxiety among patients, as reported by the Cystic Fibrosis Trust. The government's efforts to secure additional supply are vital to prevent further health complications and ensure continuous access to necessary medications. This development is particularly significant for healthcare providers who have faced challenges in prescribing and dispensing PERT due to limited supply. The proactive measures by the DHSC aim to stabilize the situation and prevent similar shortages in the future.
What's Next?
The DHSC will continue to work closely with manufacturers to resolve supply issues and ensure stable access to PERT. A new active pharmaceutical ingredient facility is under construction, expected to be operational by the end of 2026, which will enhance production capacity. The DHSC's ongoing communication with suppliers and healthcare professionals will be crucial in monitoring and addressing any further disruptions. Additionally, organizations like Pancreatic Cancer UK and the Cystic Fibrosis Trust will continue to advocate for improvements and monitor the situation to ensure patient needs are met.
Beyond the Headlines
The PERT shortage highlights the importance of robust supply chain management and the need for contingency planning in healthcare. The situation underscores the ethical responsibility of governments and pharmaceutical companies to ensure the availability of critical medications. Lessons learned from this shortage could inform future policies to prevent similar disruptions and improve healthcare resilience.
